Goserelin
FDA-approved drugAlso known as: 65807-02-5, Decapeptide I, Goserelina, Gosereline, Goserelinum, ICI-118630, ICI 118630, ICI 118,630
Goserelin (65807-02-5, Decapeptide I, Goserelina) is classified under reproductive & hypothalamic peptides, an FDA-approved drug.
Read the full guide: what the research shows on Goserelin →What the research says
Aggregated from the cited literature below. We summarize sources — we don't author claims.
Goserelin is a synthetic decapeptide analogue of luteinising hormone-releasing hormone (LHRH), also described as a GnRH (gonadotropin-releasing hormone) agonist. Research has evaluated its pharmacokinetics and clinical use in multiple hormone-dependent settings, including prostate cancer and breast cancer, and discussed roles in gynecological disorders. (PMIDs: 10926349, 42226753, 15590321)
Mechanism (as reported)
Research reported that goserelin acts as a GnRH/LHRH agonist and that its mechanism centers on sustained GnRH receptor desensitization leading to pituitary downregulation and subsequent suppression of ovarian steroid production (estradiol and progesterone described as reduced to postmenopausal levels). (PMID: 42226753; also consistent with endocrine response description in PMID: 10926349)
Key findings (each cites a source)
- A pharmacokinetic study described goserelin as a synthetic decapeptide analogue of luteinising hormone-releasing hormone (LHRH) and reported that depot formulations determine serum profile shapes through release from a biodegradable lactide-glycolide copolymer matrix. (PMID: 10926349) [PMID 10926349]
- In that pharmacokinetic study, serum goserelin after administration as an aqueous solution was reported to be rapidly absorbed and eliminated, with mean elimination half-life (t1/2beta) values reported for males and females. (PMID: 10926349) [PMID 10926349]
- That pharmacokinetic study reported no clinically relevant accumulation with multiple administration of 1-month or 3-month depot formulations. (PMID: 10926349) [PMID 10926349]
- That pharmacokinetic study reported extensive metabolism prior to excretion and described that pharmacokinetics were unaffected by hepatic impairment, while mean t1/2beta increased in patients with severe renal impairment. (PMID: 10926349) [PMID 10926349]
- The same pharmacokinetic study reported an endocrine pattern after depot administration: an initial increase in luteinising hormone (LH) and increases in serum testosterone or oestradiol, followed by decreases in LH and suppression of testosterone/oestradiol to within castrate/menopausal ranges, with continued suppression during ongoing depot treatment. (PMID: 10926349) [PMID 10926349]
- A multicenter, prospective observational real-world study in hormone treatment-naïve Chinese prostate cancer patients reported effectiveness outcomes using changes in serum testosterone and prostate-specific antigen (PSA) and reported attainment of chemical castration in a high proportion of evaluable patients. (PMID: 38318809) [PMID 38318809]
- In that prostate cancer real-world study, treatment-emergent adverse events (TEAEs) and severe TEAEs were reported with specified proportions. (PMID: 38318809) [PMID 38318809]
- A U.S. real-world evidence study using electronic medical records analyzed 3-month goserelin 10.8 mg versus monthly goserelin 3.6 mg in premenopausal breast cancer and reported that goserelin 10.8 mg was non-inferior to 3.6 mg based on observed 12-month real-world event-free survival (rwEFS) rates. (PMID: 40050524) [PMID 40050524]
- A review article stated that the mechanism of goserelin centers on sustained GnRH receptor desensitization leading to pituitary downregulation and ovarian suppression, with reduction of estradiol and progesterone to postmenopausal levels. (PMID: 42226753) [PMID 42226753]
Independent test grades
No independent third-party test data is available for Goserelin yet. Our test grades are aggregated from Finnrick, which independently tests a subset of research peptides — many approved drugs and newer or niche compounds aren't covered.
Research literature (11)
Consolidated from PubMed — each links to the original record.
- Roles of Goserelin in Gynecological Disorders.
Huang X, Gu N, Qian L, Sun F, Yang S, Xu H · Drug design, development and therapy · 2026 · PMID 42226753
- Rapidly dissolving microneedle patch embedded with long-acting microspheres for sustained release of goserelin.
Han Q, Jiao Y, Cai R, You J, Chen X, Zhang W · Journal of controlled release : official journal of the Controlled Release Society · 2025 · PMID 41213385
- Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study.
McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J · Breast cancer research and treatment · 2025 · PMID 40050524
- Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.
Chen N, Wang Z, Chen M, Ma Q, He Y, Wang Y · Cancer biology & medicine · 2024 · PMID 38318809
- Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.
Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D · The New England journal of medicine · 2015 · PMID 25738668
- Editorial comment.
Schellhammer PF · The Journal of urology · 2011 · PMID 21239016
- Goserelin.
Nursing times · 2006 · PMID 16440976
FAQ
- What is Goserelin?
- Goserelin (65807-02-5, Decapeptide I, Goserelina) is classified under reproductive & hypothalamic peptides, an FDA-approved drug. Research goals associated with it include hormonal & endocrine.
- Is Goserelin FDA-approved?
- Yes — Goserelin is approved by the FDA (marketed as 65807-02-5, Decapeptide I).
- What does the research on Goserelin say?
- peptideone aggregates 11 references from PubMed for Goserelin. The summary on this page digests them with citations; we summarize sources and make no efficacy claims.